Treats moderate to severe acute pain, including postoperative pain. Sold as Journavx. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Suzetrigine (sold as Journavx), first approved Jan 30, 2025, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Journavx | Part D | $27.3M | New | 25,894 |
| A Pilot Randomized Controlled Trial of Suzetrigine as an Adjunct to Multimodal Analgesia Following Total Knee ArthroplastyTotal Knee Arthroplasty · University of California, Irvine | Phase 4 | Not yet recruiting | Nov 10, 2026 |
| Suzetrigine (Journavx) as Multimodal Therapy for Pain Management in Adults Undergoing Surgery for Hip FractureHip Fractures (ICD-10 72.01-72.2), Post Operative Analgesia · Beth Israel Deaconess Medical Center | Phase 4 | Not yet recruiting | Oct 29, 2026 |
| Suzetrigine in TKATotal Knee Arthroplasty (TKA), Total Knee Arthroplasty \(TKA\) · Hospital for Special Surgery, New York | Phase 3 | Recruiting | Oct 8, 2026 |
| Suzetrigine for Analgesiain Arthroscopic Rotator Cuff RepairArtroscopic Surgery, Pain Management · University of Alabama at Birmingham | Phase 4 | Not yet recruiting | Oct 8, 2026 |
| Suzetrigine Following Urogynecologic Surgery: Investigation of Postoperative Pain ManagementPelvic Organ Prolapse (POP), Postoperative Pain · Aditi Talkad | Phase 4 | Not yet recruiting | Oct 2, 2026 |
| Suzetrigine Versus Standard Analgesia After Skin Cancer SurgeryPostoperative Pain, Acute Pain · University of Minnesota | Phase 4 | Not yet recruiting | Sep 25, 2026 |
| Suzetrigine Post DIEPPost-operative Pain, DIEP Flap Breast Reconstruction · Vanderbilt University Medical Center | Phase 3 | Not yet recruiting | Sep 24, 2026 |
| Suzetrigine Added to Multimodal Analgesia for Women Undergoing Minimally Invasive HysterectomyPostoperative Pain · Duke University | Phase 4 | Not yet recruiting | Sep 23, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jan 30, 2025 | JournavxNDA 219209 · New molecular entity | Vertex Pharms Inc | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
